Submit Manuscript Now
Current issue Archive Authors Profile
Research Articles Issue 1 · 2020 · pp. 201–210 · Issue page

EFFECT OF ESCITALOPRAM ALONE OR COMBINATION WITH SORAFENIB ON HEPG2 HEPATOCELLULAR CELL LINE PROLIFERATION

ZE
Zeynep Gunes OZUNAL1
YA
Yaprak DONMEZ CAKIL2
ES
Esra SAGLAM3
RA
Ranan Gulhan AKTAS4
1 Maltepe University, Faculty of Medicine , Medical Pharmacology Department ; Maltepe University, Faculty of Medicine, Cancer and stem cell research center, (MUKKAM)
2 Maltepe University, Faculty of Medicine, Histology and Embryology Department; Maltepe University, Faculty of Medicine, Cancer and stem cell research center, (MUKKAM)
3 Maltepe University, Faculty of Medicine , Medical Pharmacology Department ; Maltepe University, Faculty of Medicine, Cancer and stem cell research center, (MUKKAM)
4 Maltepe University, Faculty of Medicine, Histology and Embryology Department; Maltepe University, Faculty of Medicine, Cancer and stem cell research center, (MUKKAM)
DOI https://doi.org/10.38173/RST.2020.19.1.20:201-210
Received 03 February 2020
Revised No
Accepted 06 March 2020
Available Online 15 March 2020
Abstract
HEPATOCELLULAR CARCINOMA IS ONE OF THE MOST COMMON CANCERS. THE MAIN TREATMENT FOR HEPATOCELLULAR CANCERS IS SURGERY. DRUG TREATMENT CAN BE PERFORMED IN ADVANCED CASES AFTER SURGICAL TREATMENT OR RELAPSE THERAPY. SORAFENIB IS A DRUG THAT IS USED PRIMARILY IN THE TREATMENT OF HEPATOCELLULAR CANCER. ESCITALOPRAM IS A DRUG IN THE SEROTONIN REUPTAKE INHIBITOR GROUP USED TO TREAT DEPRESSION. THERE ARE STUDIES SHOWING THE EFFECT OF ESCITALOPRAM ON PROLIFERATION. THE PURPOSE OF THIS STUDY IS TO EVALUATE THE USE OF ESCITALOP RAM ALONE AND IN COMBINATION WITH SORAFENIB IN LIVER CANCER. THE EFFECT OF ESCITALOPRAM AND IN COMBINATION ON PROLIFERATION OF HEPATOCELLULAR CELL LINES WAS ASSESSED BY XTT PROLIFERATION ASSAY. THE HALF INHIBITING CONCENTRAT İON (IC 50) WAS CALCULATED BY REGRESSION ANALYSIS, PHOTOGRAPHED UNDER AN İNVERTED MİCROSCOPE. THE SYNERGISTIC EFFECT HAS BEEN EVALUATED. THE EFFECT ON MORPHOLOGİCAL CHANGES WAS VISUALIZED UNDER THE INVERTED MICROSCOPE. THE RESULTS OF OUR STUDY CONFIRM THE SYNERGISTIC EFFECT OF USE OF ESCITALOPRAM IN COMBINATION WITH SORAFENIB IN LIVER CANCER. PROSPECTIVE RANDOMIZED TRIALS ARE NEEDED TO EVALUATE ITS CLINICAL USE.
Keywords
ESCITALOPRAM HEPG2 PROLIFERATION SORAFENIB CANCER
Full Text
The body of this article is intentionally hidden on the public page. Please use the PDF reader or the PDF download for the complete text.
References
[1]
Aktaş G. Antibiotic Combinations and Synergistic Interactions. Türk Mikrobiyol Cem Derg 2015; 44: 47-55.
[2]
Bliss CI. The toxicity of poisons applied jointly. Ann App Biol 1939; 26: 585–615
[3]
Bruix J, Raoul JL, Sherman M, Mazzaferro V, et al . Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. J Hepatol 2012;57: 821-829.
[4]
Caraci F, Crupi R, Drago F, Spina E. Metabolic drug interactions between antidepressants and anticancer drugs: focus on selective serotonin re uptake inhibitors and hypericum extract. Curr Drug Metab 2011;12: 570-7.
[5]
Chen VC, Hsieh YH, Chen LJ, Hsu TC, Tzang BS . Escitalopram oxalate induces apoptosis in U- 87MG cells and autophagy in GBM8401 cells. J Cell Mol Med 2018; 22:1167 -78. doi: 10.1111/jcmm.13372.
[6]
Chou TC . Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58: 621-81.
[7]
Cipriani A, Furukawa TA, Salanti G, Chaimani A et al . Comparative efficacy and acc eptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 2018; 391:1357-66.
[8]
Dikmen M, Cantürk Z, Oztürk Y. Escitalopram oxalate, a selective serotonin reup take inhibitor, exhibits cytotoxic and apoptotic effects in glioma C6 cells. Acta Neuropsychiatr 2011; 23: 173-8.
[9]
Ianevski A, He L, Aittokallio T, Tang J. SynergyFinder: a web application for analyzing drug combination dose -response matrix data. Bioinformatics 2017; 33:2413 -15. doi:10.1093/bioinformatics/btx162.
[10]
Jin G, Wong ST . Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines. Drug Discov Today 2014;19:637-44. doi:10.1016/j.drudis.2013.11.005. Epub 201 3 Nov 14.
[11]
Kirino E . Escitalopram for the management of major depressive disorder: a review of its efficacy, safety, and patient acceptability. Patient Prefer Adherence 2012; 6: 853.
[12]
Kuwahara J, Yamada T, Egashira N, Ueda M, et al . Comparison of the Anti-tumor Effects of Selective Serotonin Reuptake Inhibitors as Well as Serotonin and Norepinephrine Reuptake Inhibitors in Human Hepatocellular Carcinoma Cells. Biol Pharm Bull 2015; 38:1410 -4. doi: 10.1248/bpb.b15 - 00128.21)
[13]
Llovet JM. Updated treatment approa ch to hepatocellular carcinoma. J Gastroenterol 2005; 40: 225- 35.
[14]
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, et al. Sorafenib in advanced hepatocellular carcinoma 2008; N Engl J Med 359: 378-90.
[15]
Li YY, Jones SJ. Drug repositioning for personalized medicine. Genome Med 2012; 4: 27.
[16]
Rao N. The clinical pharmacokinetics of escitalopram. Clin Pharmacokinet 2007; 46: 281-90.
[17]
Raza A, SoodGK . Hepatocellular carcinoma review: current treatment, and evidence -based medicine. World J Gastroenterol 2014; 20: p. 4115-27.
[18]
Sanchez C, Reines EH, Montgomery SA . A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike? Int Clin Psychopharmacol . 2014; 29:185 -96. doi:10.1097/YIC.0000000000000023.
[19]
Smith, HR. Depression in cancer patients: Pathogenes is, implications and treatment. Oncol Lett 2015; 9: 1509-14.
[20]
Villanueva A, Llovet JM . Targeted therapies for hepatocellular carcinoma. Gastroenterology. 2011; 140:1410-26. doi: 10.1053/j.gastro.2011.03.006. Epub 2011 Mar 13.